Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × IDH1 Mutation Myeloid Neoplasms × ivosidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 7 Myeloproliferative Disorders 3 Recurrence 2 Myelodysplastic Syndromes 2 Hematologic Neoplasms 2 Pancreatic Ductal Adenocarcinoma 1 Leukemia 1 IDH1-Mutated Malignancies 1 IDH1 Mutation Myeloid Neoplasms 1 Glioma 1 Cholangiocarcinoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03564821 2025-11-04

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Massachusetts General Hospital

Phase 1 Completed

IDH1 Mutation Myeloid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡